`
`Page 1 of 1
`
`Confirmation Number
`Application Number
`Filing Date
`First Named Inventor
`Group Art Unit
`Examiner Name
`Attorney Docket Number
`US PATENT DOCUMENTS
`U.S. Patent Document
`
`1597
`13/034340
`02-24-2014
`Alan H. Auerbach
`1621
`San Ming R. Hui
`CGR5001 USCNT1
`
`Examiner
`Initials
`
`Cite
`No. 1
`
`Name of Patentee or Applicant
`of Cited Document
`
`Number
`
`Kind Code'
`(if known)
`
`Pages. Columns. Lines.
`where relevant passages or
`relevant figures appear
`
`Examiner
`Initials
`
`Cite
`No. 1
`
`Name of Patentee or
`Applicant of Cited Document
`
`Office'
`
`Number4 KindCode5
`
`FOREIGN PATENT DOCUMENTS
`Foreign Patent Document
`
`Pages. Columns. Lines.
`where relevant passages
`or relevant figures
`appear
`
`T'
`
`OTHER PRIOR ART· NON PATENT LITERATURE DOCUMENTS
`Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate),
`title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s),
`volume-issue number(s), publisher, city and/or country where published
`
`T2
`
`Examiner
`'s
`Initials*
`
`Cite
`No. 1
`
`Statement of Opposition, Actavis Group PTC ehf
`Statement of Opposition, Alfred E. Tiefenbacher
`Statement of Opposition, Alison Gallafent
`Statement of Opposition, Arnold Siedsma
`Statement of Opposition, Cabinet Lavoix
`Statement of Opposition, Galenicum Health, S.L.
`Statement of Opposition, Generics Ltd.
`Statement of Opposition, Helm AG
`Statement of Opposition, Hetero DruQs
`Statement of Opposition, lsenbruck Basi Horschler LLP
`Statement of Opposition, Laboratories Leon Farma, S.A.
`Statement of Opposition, Maiwald Patentanwalts GmbH
`Statement of Opposition, Stada Arzneimittel
`Statement of Opposition, Synthon B.V.
`Statement of Opposition, Teva Pharmaceutical Industries, Ltd.
`Statement of Opposition, Zentiva k.s.
`
`I Examiner
`
`S1snature
`
`Date
`Considered
`
`MYLAN PHARMS. INC. EXHIBIT 1075 PAGE 1